Iron chelators for clinical use.
Tilbrook
G S
GS
Department of Pharmacy, King's College London, University of London, UK.
Hider
R C
RC
D001692:Biological Transport; D003676:Deferoxamine / Q000737:chemistry; D016503:Drug Delivery Systems; D004492:Edetic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D005290:Ferric Compounds / Q000378:metabolism; D016166:Free Radical Scavengers / Q000737:chemistry; D006801:Humans; D007501:Iron / Q000378:metabolism / Q000633:toxicity*; D007502:Iron Chelating Agents / Q000737:chemistry / Q000627:therapeutic use*; D019190:Iron Overload; D008024:Ligands; D008970:Molecular Weight; D010084:Oxidation-Reduction; D004369:Pentetic Acid / Q000737:chemistry; D011929:Razoxane / Q000737:chemistry; D012995:Solubility; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D005290:Ferric Compounds; D016166:Free Radical Scavengers; D007502:Iron Chelating Agents; D008024:Ligands; C092592:N,N'-bis(dibenzyl)ethylenediaminediacetic acid; C037740:N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid; D011929:Razoxane; D004369:Pentetic Acid; D004492:Edetic Acid; D007501:Iron; D003676:Deferoxamine